secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001477932-23-007651
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Bionexus Gene Lab appoints Chi Yuen Leong as CEO and director, effective Oct 12, 2023
--------------------------------------------------------------------------------

- Chi Yuen Leong appointed CEO and director effective October 12, 2023; annual compensation $24,000.
- Leong previously served as President and director from company inception to August 2022.
- He has no family relationships or reportable transactions with the company.
- Leong brings experience from CEO role at US Arem Pacific Corp (2009-2015) and background in biotechnology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223007651/0001477932-23-007651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223007651/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-007651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer